Why Turn Therapeutics Inc.’s (TTRX) Stock Is Down 5.79%
As of Friday, November 20, Turn Therapeutics Inc.’s TTRX share price has dipped by 5.79%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Michael Rose
Michael Rose
Michael Rose
Michael Rose
| Share Statistics | TTRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $247.5 | $421.5 | 32% |
|
| Shares Out (Mil) | 30.1 | 46.9 | 37% |
|
| Institutional Ownership | 12.0% | 82.0% | 7% |
|
| Float (Mil) | 11.9 | 49.2 | 22% |
|
| Beta | na | 0.68 | na |
|
| Avg Daily Volume (000s) | 101 | 347 | 36% |
|
| Price Change (52-week) |
186.0% | 49.3% | 99% |
|
| Growth | TTRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | na | (1.3%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TTRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $275 | na |
|
| Net Income (TTM) (Mil) | ($13) | ($11) | 27% |
|
| EPS (TTM) | ($0.434) | ($0.700) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($7) | 25% |
|
| Net Cash Flow (TTM) (Mil) | $7 | $1 | 56% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $6 | 25% |
|
| Enterprise Value (Q1) (Mil) | $268 | $331 | 29% |
|
| Valuation | TTRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 42.61 | 2.08 | 99% |
|
| P/E | na | 20.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TTRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.5% | na |
|
| Net Margin | na | 3.6% | na |
|
| ROA | (123.7%) | (23.8%) | 4% |
|
| ROE | (412.3%) | (24.2%) | 1% |
|
| Liabilities to Assets | 65.2% | 31.6% | 61% |
|
| F-Score | 2 | 3 | 7% |
|
Turn Therapeutics Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors